Pivekimab

Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC) . Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) [1][2].

Product Specifications

CAS Number

[2234335-84-1]

UNSPSC

12352203

Target

ADC Antibody; Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pivekimab.html

Purity

97.19

Solubility

10 mM in DMSO

Smiles

[Pivekimab]

Molecular Weight

(145.98 kDa)

References & Citations

[1]Patrick ZM, et, al. Methods of treatment using anti-CD123 immunoconjugates. WO2020092533.|[2]Poussard, et al. Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model. Blood 142 (2023) : 2791.